

Stephen Van Deventer
5347 Kew Cliff Road
West Vancouver, British Columbia, V7W 1M3

EARLY WARNING NEWS RELEASE

Vancouver, British Columbia, July 4, 2017, Stephen Van Deventer ("**Mr. Van Deventer**"), the Chairman and Chief Executive Officer of PreveCeutical Medical Inc., formerly Carrara Exploration Inc. (the "**Issuer**"), makes the following announcement in accordance with National Instrument 62-103 *The Early Warning System and Related Take Over Bids* and National Instrument 62-104 *Take-Over Bids and Issuer Bids*.

Mr. Van Deventer announces that on June 30, 2017, he acquired beneficial ownership and control over 16,972,100 common shares in the capital of the Issuer at a deemed issuance price of \$0.50 per share, pursuant to an amalgamation agreement dated March 21, 2017, whereby the Issuer acquired all of the issued and outstanding shares of 1050962 B.C. Ltd., formerly PreveCeutical Medical Inc. (the "**Transaction**"). Of the 16,972,100 shares acquired, 7,800,000 were acquired by Mr. Van Deventer in his personal name and 9,172,100 were acquired by Cornerstone Global Partners Inc., which is controlled by Mr. Van Deventer. The common shares of the Issuer (the "**PreveCeutical Shares**") are listed for trading on the Canadian Securities Exchange, however, the Transaction did not occur on a stock exchange or other market that represents a published market for securities.

Immediately before the completion of the Transaction, Mr. Van Deventer beneficially owned or controlled 360,000 PreveCeutical Shares, representing 4.36% of the then issued and outstanding PreveCeutical Shares. As a result of the Transaction, Mr. Van Deventer beneficially owns and controls 16,972,100 PreveCeutical Shares, together with 250,000 common share stock options and 360,000 common share purchase warrants, representing 34.64% (35.44% on a partially diluted basis) of the currently issued and outstanding PreveCeutical Shares.

Mr. Van Deventer (and Cornerstone Global Partners Inc.) acquired the PreveCeutical Shares for investment purposes. However, Mr. Van Deventer (or Cornerstone Global Partners Inc.) will review their holdings from time to time and may, in the future, increase or decrease their ownership or control over securities of the Issuer as circumstances dictate.

Upon the completion of the Transaction, the Issuer became a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers and that markets nutraceutical products to such consumers. The Issuer has one product for sale, the CELLB9™, which is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide, obtained from Caribbean blue scorpion venom. Management of the Issuer, led by Mr. Van Deventer, is currently working to research and develop other health and wellness products utilizing peptides contained in Caribbean blue scorpion venom and cannabinoids (the chemical constituents of marijuana).

An early warning report will be filed under the Issuer's profile on the SEDAR website at www.sedar.com. A copy of the early warning report can also be obtained from the contact below.

The Issuer's head office is located at Suite 2200, 1177 West Hastings Street, Vancouver, British Columbia, V6E 2K3.

For more information contact:

Stephen Van Deventer
(604) 306-9669